麻豆传媒

-- a compound of 17 Chinese herbs -- reduced the risk of developing diabetes by 41% in people with impaired glucose tolerance and multiple metabolic abnormalities. (JAMA Internal Medicine)

Nearly 2 years after getting a course of teprotumumab (Tepezza) infusions, 82% of patients remained free of any additional like steroids or surgery, according to research presented at the ENDO 2024 meeting. Catch up on more research from the meeting here. (Thyroid)

Here are common myths about . (The Hill)

Cushing's disease patients who continued on in the randomized withdrawal portion of the phase III GRACE trial were more likely to maintain blood pressure control than those switched to placebo, said Corcept Therapeutics.

Novo Nordisk defended its $1,000 list price for a (Ozempic) to Sen. Bernie Sanders (I-Vt.), saying the development of GLP-1 drugs required billions in upfront investment. (Becker's Hospital Review)

In other news, Novo Nordisk sued nine more spas, clinics, and pharmacies in the U.S. for of its diabetes and obesity drug semaglutide. (Reuters)

A decade after surgery for severe obesity (BMI 50-60), after biliopancreatic diversion with duodenal switch, but Roux-en-Y-gastric bypass had a better risk profile. (JAMA Network Open)

Experts raised annual to reach $150 billion by the early 2030s. (Reuters)

Comment